etoposide + durvalumab + carboplatin + cisplatin

**etoposide + durvalumab + carboplatin + cisplatin** is an experimental four-drug combination that unites a topoisomerase II inhibitor (etoposide), an immune checkpoint inhibitor (durvalumab), and two platinum-based chemotherapeutics (carboplatin and cisplatin). Etoposide induces DNA strand breaks by inhibiting topoisomerase II, leading to DNA damage and apoptosis. Durvalumab is a monoclonal antibody against programmed death-ligand 1 (PD-L1), facilitating antitumor immune responses. Carboplatin and cisplatin both form DNA crosslinks, interfering with DNA replication and transcription, and ultimately promoting apoptosis, although they differ in their toxicity profiles and pharmacokinetics. This specific quadruple regimen is not a standard or guideline-endorsed protocol; trials and regulatory approvals for first-line extensive-stage small cell lung cancer (ES-SCLC) involve durvalumab with etoposide plus either carboplatin or cisplatin, but not both carboplatin and cisplatin together with etoposide and durvalumab[1][4][5][7]. Therefore, this four-drug combination represents an investigational or theoretical regimen rather than an established therapy.